

# 心筋梗塞の傾向は若年者と高齢者とで異なる

FAST-MI:STEMIの死亡率は全体的に改善しているが新たなデータから若年者お よび女性のMIが増加する心配な傾向が示された

FAST-MI: Mortality rates from STEMI improving overall but new data shows worrying trend of increasing MIs in young people and women

2012年European Society of Cardiology学会で発表され同時にJAMAに掲載されたFAST-MI (4つのフランス国内レジストリ)の結果、この15年間でST上昇型心筋梗塞(STEMI)治療の成 功率が上昇し、死亡率が68%低下(13.7%から4.4%)していることが示された。プライマリ経皮 的冠動脈インターベンションや再灌流療法の使用で補正した後であっても早期死亡率は実質 的に(>60%)低下しており、その患者背景、患者の行動および組織や治療提供などが大きく影 響していた。再灌流療法を施行されなかった患者においても、STEMI死亡率は50%を超えて低 下した。このスタディにより、若年患者(60歳未満)、特にMIを発症する女性の割合が実質的に増 加している心配な結果が示された。60歳未満の女性の割合は2倍(12%から25%)に、50歳未 満の女性の割合は3倍(3.7%から11.1%)に増加した。若年女性患者の中で急速に増加してい るのは喫煙者(1995年には37%、2012年には73%)、およびほたは肥満者(18%から27%)の割 合であった。急な胸痛を発症した患者の行動もまた変化しており、医療救助への連絡がより迅速 (2000年には中央値が120分であったものが2010年には74分)になった。

## Full Text

The FAST-MI study which evaluated data from four French nationwide registries of ST-elevation myocardial infarction (STEMI) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics

Even after adjusting for the use of primary percutaneous coronary intervention (PCI) and reperfusion therapy, there still remained a substantial decrease in early mortality rate (>60%), underlining the importance of population characteristics, patient behavior and the general organization and provision of care. Even in patients not having reperfusion therapy, STEMI mortality rate decreased by more than

The results were presented here in Munich by Dr. Nicolas Danchin representing the French registries USIK 1995, USIC 2000, FAST-MI 2005 and FAST-MI 2010.

Explaining the purpose of the combined analysis, Dr. Danchin said: "Spectacular progress has been made in the treatment of ST-elevation myocardial infarction. Most of this progress is generally attributed to the more frequent administration of reperfusion therapy, particularly by primary PCI. Using data from these four STEMI registries, we sought to determine the extent of improvement in survival, and whether factors other than reperfusion therapy contributed to the decline in early mortality.

The analysis did indeed show a notable change in population characteristics: a progressive three-year average decease in age, and a lower proportion of patients with associated conditions or previously known heart disease. This was mainly explained by a substantial increase in the proportion of younger patients (ie, below 60 years of age), especially women; the proportion of women under 60 years of age doubled (from 12% to 25%), and that of women under 50 years tripled (from 3.7% to 11.1%).

A fast growing proportion of young women were current smokers (37% in 1995, 73% in 2010) and/or obese (18% to 27%).

The behavior of patients confronted with acute chest pain also changed, with a more rapid call for medical help (from a median of 120 minutes in 2000 to 74 minutes in 2010). Similarly, more patients called the emergency medical system (SAMU in France) - 23% in 2000 and 49% in 2010.

More patients also received reperfusion therapy to reopen the blocked artery - 75% in 2010, compared with 49% in 1995, with a five-fold increase in use of primary PCI (from 12% to 60%).

Other changes were observed in the early management of STEMI patients, with more receiving antiplatelet agents or low molecular weight heparin to help dissolve the clot, as well as other recommended medications (particularly statins, whose use increased from 10% to 90%).

" Overall," said Dr. Danchin, "the major decline in early mortality for STEMI patients should not be attributed only to improved delivery of reperfusion treatment. The improvement also reflects a profound and preoccupying change in the type of patient having a heart attack, with a particular increase in the number of young women. This increase is concomitant with an increased prevalence of smoking and obesity.'

"The successes achieved in older patients and the changes in patient profile suggest that, to reduce the rate of STEMI mortality even further, future efforts should be directed at making healthcare providers and the general public more aware of the growing proportion of younger females among STEMI patients. Future preventive measures might be specifically targeted towards this group.

### **Conference News**

2011年の地震後に心不全のピークが持続

初めてのアンジオテンシン受容体ネプリライシン 阻害薬は有望であることが示された

僧帽弁閉鎖不全症に対するMitraClipの有望なデータ

Prasugrelはクロピドグレルよりもイベントを 減少させなかった

アスピリン反応性を追加することによりクロピ ドグレルの予測値が上昇する

[News 06] FFRctは既存の方法よりも優れている可能性 が示された

ステント留置後で抗血小板薬内服中の患者 におけるアスピリン中止は安全である

心原性ショックにおいて大動脈内バルーン パンピングの生存率に関する有益性はない

FFRガイド下インターベンションは緊急血行 再建術を減少させる

[News 10] 大規模レジストリにおいてもTAVI後の有害 イベントは低かった

TAVIは重症大動脈弁狭窄症患者のQOLを 改善する

心筋梗塞の傾向は若年者と高齢者とで異なる